Trial Profile
Effects of Ipragliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus; Weight gain
- Focus Pharmacodynamics
- Acronyms SUMS-ADDIT-1
- 26 Jun 2018 Results (n=50) presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2018 Status changed from active, no longer recruiting to completed, according to results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.